A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer

NCT02149524 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

875

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2 Positive Early or Locally Advanced Breast Cancer

Interventions

DRUG: Herceptin (trastuzuamb)
DRUG: SB3 (proposed trastuzumab biosimilar)

Sponsor

Samsung Bioepis Co., Ltd.